Cytodyn (CYDY) is a leading biotechnology business based in the US. It opened the day at $0.39 after a previous close of $0.39. During the day the price has varied from a low of $0.29 to a high of $0.39. The latest price was $0.33 (25 minute delay). Cytodyn is listed on the OTCQB and employs 9 staff. All prices are listed in US Dollars.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.10 - $0.49 |
|---|---|
| 50-day moving average | $0.25 |
| 200-day moving average | $0.17 |
| Wall St. target price | $4.00 |
| PE ratio | 0 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.00 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.328 from 2025-05-06
| 1 week (2025-05-01) | 9.33% |
|---|---|
| 1 month (2025-04-08) | 49.09% |
| 3 months (2025-02-07) | 56.19% |
| 6 months (2024-11-08) | 173.33% |
| 1 year (2024-05-08) | 118.67% |
|---|---|
| 2 years (2023-05-08) | 21.48% |
| 3 years (2022-05-06) | 0.39 |
| 5 years (2020-05-08) | 2.92 |
Valuing Cytodyn stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cytodyn's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cytodyn's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.1 million.
The EBITDA is a measure of a Cytodyn's overall financial performance and is widely used to measure a its profitability.
| Gross profit TTM | $-20,633,000 |
|---|---|
| Return on assets TTM | 32.15% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $-0.08 |
| Market Capitalization | $358.9 million |
TTM: trailing 12 months
We're not expecting Cytodyn to pay a dividend over the next 12 months.
Over the last 12 months, Cytodyn's shares have ranged in value from as little as $0.1 up to $0.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while Cytodyn's is 1.331. This would suggest that Cytodyn's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
CytoDyn Inc. , a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.